➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Mallinckrodt
Johnson and Johnson
Merck
McKinsey

Last Updated: July 16, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRELSTAR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Trelstar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01467882 Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty Completed Debiopharm International SA Phase 3 2012-04-01 The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).
NCT02090114 RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study) Recruiting National Cancer Institute (NCI) Phase 2 2014-06-01 Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide or abiraterone in men with metastatic CRPC who previously progressed on either of these agents. The study will enroll two cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A); and men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B).
NCT02090114 RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study) Recruiting Sidney Kimmel Comprehensive Cancer Center Phase 2 2014-06-01 Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide or abiraterone in men with metastatic CRPC who previously progressed on either of these agents. The study will enroll two cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A); and men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B).
NCT02286921 Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Recruiting United States Department of Defense Phase 2 2015-01-01 Asymptomatic men with progressive metastatic CRPC post- treatment with abiraterone acetate (pre-chemotherapy for metastatic disease) will be treated on a randomized, multi-Institutional open label study to determine if treatment with intramuscular T given on a dose/schedule designed to result in rapid cycling from the polar extremes of supraphysiologic to near castrate levels [i.e. Bipolar Androgen Therapy (BAT)] will improve primary and secondary objectives vs. enzalutamide as standard therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trelstar

Condition Name

Condition Name for Trelstar
Intervention Trials
Prostate Cancer 4
Castration Resistant Metastatic Prostate Cancer 2
Central Precocious Puberty 1
Stage IIB Prostate Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trelstar
Intervention Trials
Prostatic Neoplasms 8
Puberty, Precocious 1
Adenocarcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trelstar

Trials by Country

Trials by Country for Trelstar
Location Trials
United States 25
Chile 1
Canada 1
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trelstar
Location Trials
Maryland 4
California 3
New York 2
New Jersey 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trelstar

Clinical Trial Phase

Clinical Trial Phase for Trelstar
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trelstar
Clinical Trial Phase Trials
Recruiting 5
Not yet recruiting 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trelstar

Sponsor Name

Sponsor Name for Trelstar
Sponsor Trials
National Cancer Institute (NCI) 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2
United States Department of Defense 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trelstar
Sponsor Trials
Other 8
Industry 4
U.S. Fed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Johnson and Johnson
Mallinckrodt
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.